Has the cervical cancer vaccine been approved for marketing?

It is reported that a few days ago, the website of the US Food and Drug Administration officially issued an announcement to approve the application for import registration of the preventive biological cervical cancer vaccine "Silas", and the cervical cancer vaccine was approved to be listed and supplied to the national market.

It is reported that cervical cancer is one of the most common malignant tumors in women. Globally, a new case is found every minute on average, and a woman dies of cervical cancer every two minutes. China accounts for more than 28% of cervical cancer cases in the world, with 654.38+million new cases and 30,000 deaths, making it the third most common cancer among women aged 654.38+05 to 44.

According to experts, 99.7% of cervical cancer is caused by human papillomavirus infection. The vaccine approved by GlaxoSmithKline to enter China, commonly known as bivalent HPV vaccine, can effectively prevent the infection of two genotypes of human papillomavirus-16 and human papillomavirus-18, which account for almost 70% of all cases of cervical cancer and precancerous lesions.

Relevant persons also said that at present, China is also carrying out basic research and development of human papillomavirus vaccine, and one or two vaccines are already in clinical trials. More vaccines will be approved to enter the market in the future. Through market competition, the price of HPV vaccine will come down, and it may be included in medical insurance at that time.